Cases & Deals

  • Home
  • Practices
  • Incyte and Innocare announce collaboration and license agreement for Tafasitimab in Greater China

Share

Incyte and Innocare announce collaboration and license agreement for Tafasitimab in Greater China

August 2021

Client(s) Incyte Corporation

Jones Day represents Incyte Corporation in an exclusive license out of rights to conduct clinical trials, seek regulatory approval, and commercialize products containing Tafasitamab, an anti-CD19 monoclonal antibody, in Greater China. The license includes a sublicense to rights licensed to Incyte from MorphoSys, which has obtained approval for the product under the trademark MONJUVI®. The agreement includes coordinated clinical trial efforts, cost sharing, as well as reversionary and co-promotion rights of Incyte and a parent guarantee by Innocare.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.